Efficacy Study of Single-Dose Levalbuterol Tartrate HFA MDI Vs Placebo in Subjects 18 Years and Older With EIB
Status:
Completed
Trial end date:
2006-02-01
Target enrollment:
Participant gender:
Summary
To determine if administration of levalbuterol tartrate HFA MDI in subjects with EIB will be
effective in the prevention of EIB and be safe and well-tolerated.